Cyclic GMP sodium
Based on 1 publication(s) in Google Scholar
Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.89%
- CAS. Nr.: 40732-48-7
- Formel: C10H11N5NaO7P
- Molecular Weight:367.19
-
Speicherung:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Cyclic GMP sodium
MoreAlle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Human Endogenous Metabolite |
ACh can stimulate the accumulation of cyclic GMP (cGMP) sodium, thereby activating cGMP-mediated protein kinases. Increased cGMP causes a decrease in Ca ion influx, which shortens the action potential and inhibits ICa. Cyclic GMP sodium (1 μM; 3-5 min) can activate cGMP-stimulated phosphodiesterases when acting synergistically with Isoprenaline (HY-B0468), reversing cAMP-mediated enhancement or inhibiting cAMP-induced inward calcium current (ICa)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 40732-48-7
-
Appearance Solid
-
Molecular Weight 367.19
-
Formel C10H11N5NaO7P
-
Color White to off-white
-
SMILES
O[C@@H]([C@H](N1C=NC2=C1N=C(N)NC2=O)O[C@@H]3CO4)[C@@H]3OP4([O-])=O.[Na+]
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Acta Neuropathol Commun
Hyperoside mitigates photoreceptor degeneration in part by targeting cGAS and suppressing DNA-induced microglial activation. [Abstract]2024 May 16;12(1):76. PMID: 38755736
Lösungsmittel & Löslichkeit
H2O : 12.5 mg/mL (34.04 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Francis SH, et al. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010 Sep;62(3):525-63. [Content Brief]
[2]. Friebe A, et al. cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development. Naunyn Schmiedebergs Arch Pharmacol. 2020 Feb;393(2):287-302. [Content Brief]
[3]. Hartzell HC, et al. Opposite effects of cyclic GMP and cyclic AMP on Ca2+ current in single heart cells. Nature. 1986 Sep 18-24;323(6085):273-5. [Content Brief]
[4]. Chintala MS, et al. Cyclic GMP but not cyclic AMP prevents renal platelet accumulation after ischemia-reperfusion in anesthetized rats. J Pharmacol Exp Ther. 1994 Dec;271(3):1203-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.7234 mL | 13.6169 mL | 27.2339 mL | 68.0846 mL |
| 5 mM | 0.5447 mL | 2.7234 mL | 5.4468 mL | 13.6169 mL | |
| 10 mM | 0.2723 mL | 1.3617 mL | 2.7234 mL | 6.8085 mL | |
| 15 mM | 0.1816 mL | 0.9078 mL | 1.8156 mL | 4.5390 mL | |
| 20 mM | 0.1362 mL | 0.6808 mL | 1.3617 mL | 3.4042 mL | |
| 25 mM | 0.1089 mL | 0.5447 mL | 1.0894 mL | 2.7234 mL | |
| 30 mM | 0.0908 mL | 0.4539 mL | 0.9078 mL | 2.2695 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.